Trials / Recruiting
RecruitingNCT06815497
Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer
Phase II Non-Randomized, Unblinded, Single-Center Trial of Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer Versus Historical Best Supportive Care
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 33 (estimated)
- Sponsor
- Tyler J Curiel · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary study objective is to assess progression-free survival in patients with ovarian cancer receiving telmisartan plus selected standard of care chemotherapy regimens versus historical controls.
Detailed description
This is an open label, single-arm Phase II trial of telmisartan plus selected standard of care chemotherapy regimens containing an anthracycline or taxane. The primary study objective is to assess progression-free survival.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Telmisartan | Telmisartan will be introduced as a 40 mg tablet to be taken orally once daily. In participants not experiencing telmisartan dose limiting toxicity, the dose will be escalated to a maximum of 80 mg |
Timeline
- Start date
- 2026-01-21
- Primary completion
- 2027-04-14
- Completion
- 2029-05-14
- First posted
- 2025-02-07
- Last updated
- 2026-01-28
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06815497. Inclusion in this directory is not an endorsement.